var data={"title":"Complications of mannitol therapy","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Complications of mannitol therapy</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/contributors\" class=\"contributor contributor_credentials\">Richard H Sterns, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/contributors\" class=\"contributor contributor_credentials\">Michael Emmett, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/contributors\" class=\"contributor contributor_credentials\">John P Forman, MD, MSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Oct 19, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=mannitol-drug-information\" class=\"drug drug_general\">Mannitol</a>, given as a hypertonic solution, is primarily used in the treatment of cerebral edema and glaucoma. Although generally well tolerated, a variety of fluid, electrolyte, and renal complications can occur if the patient is not carefully monitored. (See <a href=\"topic.htm?path=evaluation-and-management-of-elevated-intracranial-pressure-in-adults#H30\" class=\"medical medical_review\">&quot;Evaluation and management of elevated intracranial pressure in adults&quot;, section on 'Mannitol'</a> and <a href=\"topic.htm?path=angle-closure-glaucoma#H18\" class=\"medical medical_review\">&quot;Angle-closure glaucoma&quot;, section on 'Management'</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">COMPLICATIONS</span></p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Volume depletion and hypernatremia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=mannitol-drug-information\" class=\"drug drug_general\">Mannitol</a> is freely filtered by the glomerulus and does not undergo tubular reabsorption. Thus, it acts as an osmotic diuretic, increasing urinary losses of both sodium and electrolyte-free water. Lack of replacement of the fluid losses can lead to both volume depletion and hypernatremia that can be severe [<a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/1\" class=\"abstract_t\">1</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Volume expansion, hyponatremia, hyperkalemia, hypokalemia, and metabolic acidosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>If very high doses of hypertonic <a href=\"topic.htm?path=mannitol-drug-information\" class=\"drug drug_general\">mannitol</a> are infused, or if the drug is given to patients with preexisting renal failure, mannitol is retained in the circulation [<a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/2-4\" class=\"abstract_t\">2-4</a>]. The ensuing rise in plasma osmolality, similar to that produced by hyperglycemia, results in the osmotic movement of water and potassium out of cells leading to extracellular fluid volume expansion (and possibly pulmonary edema), hyponatremia, metabolic acidosis (by dilution), and hyperkalemia [<a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/5,6\" class=\"abstract_t\">5,6</a>]. Water losses from brain cells cause neurologic symptoms. Volume expansion and dilutional hyponatremia, without neurologic symptoms, can also be induced when isotonic mannitol is used as a flushing solution during transurethral resection of the prostate or bladder. (See <a href=\"topic.htm?path=hyponatremia-following-transurethral-resection-or-hysteroscopy\" class=\"medical medical_review\">&quot;Hyponatremia following transurethral resection or hysteroscopy&quot;</a>.)</p><p>The rise in the plasma potassium concentration following hypertonic <a href=\"topic.htm?path=mannitol-drug-information\" class=\"drug drug_general\">mannitol</a> is due to the movement of potassium out of the cells into the extracellular fluid via two mechanisms [<a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/6\" class=\"abstract_t\">6</a>]: (1) the rise in cell potassium concentration induced by water loss favors passive potassium exit through potassium channels in the cell membrane; and (2) the frictional forces between solvent (water) and solute can result in potassium being carried out through the water pores in the cell membrane (a process that is called solvent drag). A similar process can occur with acute hypernatremia [<a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/7\" class=\"abstract_t\">7</a>] and also largely accounts for the hyperkalemia that is commonly seen with marked hyperglycemia in uncontrolled diabetes mellitus [<a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/8,9\" class=\"abstract_t\">8,9</a>]. (See <a href=\"topic.htm?path=diabetic-ketoacidosis-and-hyperosmolar-hyperglycemic-state-in-adults-clinical-features-evaluation-and-diagnosis\" class=\"medical medical_review\">&quot;Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Clinical features, evaluation, and diagnosis&quot;</a>.)</p><p>If kidney function is normal, the transient shift of potassium out of cells due to <a href=\"topic.htm?path=mannitol-drug-information\" class=\"drug drug_general\">mannitol</a> seldom leads to hyperkalemia. A study of 45 patients treated for several days with mannitol (average dose, 28 g every six hours) for neurosurgical conditions found only one patient (2.4 percent) with a serum potassium above 5.5 <span class=\"nowrap\">meq/L</span> on the first day, and no patients with hyperkalemia on subsequent days [<a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/10\" class=\"abstract_t\">10</a>]. By contrast, 22 percent of patients developed hypokalemia (serum potassium &lt;3.5 <span class=\"nowrap\">meq/L)</span> on the first day, and this proportion increased to 52 percent by the third day.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Plasma osmolal gap</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The concentration of <a href=\"topic.htm?path=mannitol-drug-information\" class=\"drug drug_general\">mannitol</a> in the plasma can be estimated from an increase in the plasma osmolal gap, which is the difference between the measured plasma osmolality (which includes the contribution of mannitol) and the calculated plasma osmolality [<a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/11,12\" class=\"abstract_t\">11,12</a>]. The latter assumes that sodium salts (chloride and bicarbonate), glucose, and urea nitrogen are the primary solutes in the plasma and can be estimated from the following formula: </p><div class=\"formulaContainer\"><div class=\"formula\"><p> &#160; &#160; &#160;Calculated Posm &#160; = &#160; 2 x plasma Na <span class=\"nowrap\">(meq/L)</span> &#160;+ &#160;<span class=\"nowrap\">[Glucose]/18</span> &#160;+ &#160;blood urea <span class=\"nowrap\">nitrogen/2</span>.8</p></div></div><p>The plasma sodium is multiplied by two to account for accompanying anions (chloride and bicarbonate) and dividing by 18 and 2.8 for the glucose and blood urea nitrogen convert units of <span class=\"nowrap\">mg/dL</span> into <span class=\"nowrap\">mmol/L</span> [<a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/11\" class=\"abstract_t\">11</a>]. The corrections for glucose and blood urea nitrogen are not necessary in countries that report the concentrations in <span class=\"nowrap\">mmol/L</span>.</p><p>A number of other formulas have been used to estimate the plasma osmolal gap. There appears to be no significant difference between the accuracy of the different formulas and their correlation with plasma <a href=\"topic.htm?path=mannitol-drug-information\" class=\"drug drug_general\">mannitol</a> concentrations [<a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/13\" class=\"abstract_t\">13</a>]. The plasma osmolal gap, which is also elevated in other disorders, should not be allowed to exceed 55 <span class=\"nowrap\">mosmol/kg</span> when mannitol is used in the treatment of cerebral edema [<a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"topic.htm?path=serum-osmolal-gap\" class=\"medical medical_review\">&quot;Serum osmolal gap&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Acute kidney injury</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with marked <a href=\"topic.htm?path=mannitol-drug-information\" class=\"drug drug_general\">mannitol</a> accumulation (plasma osmolal gap greater than 60 to 75 <span class=\"nowrap\">mosmol/kg,</span> which reflects a plasma mannitol concentration above 1080 <span class=\"nowrap\">mg/dL)</span> may develop reversible acute kidney injury (AKI, or acute renal failure) [<a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/3,14-16\" class=\"abstract_t\">3,14-16</a>]. This complication is essentially limited to patients treated with more than 200 to 300 g of mannitol per day [<a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/17,18\" class=\"abstract_t\">17,18</a>]. The required dose varies with baseline renal function. AKI in patients with normal baseline kidney function is usually seen when the total mannitol dose exceeds 1100 g. By contrast, much smaller doses (&gt;300 g) can precipitate AKI in patients with preexisting kidney disease.</p><p>The incidence of AKI in patients treated with <a href=\"topic.htm?path=mannitol-drug-information\" class=\"drug drug_general\">mannitol</a> has ranged from 6 to 11 percent in various studies [<a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/19-21\" class=\"abstract_t\">19-21</a>]. The existence of comorbid conditions (eg, heart failure, diabetes, preexisting kidney disease) appear to increase the risk. The following studies illustrate the range of findings:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A prospective study of 95 patients treated with <a href=\"topic.htm?path=mannitol-drug-information\" class=\"drug drug_general\">mannitol</a> for increased intracranial pressure caused by a variety of insults, including trauma, found that 11 patients (11.6 percent) developed AKI (defined as a 0.5 <span class=\"nowrap\">mg/dL</span> [44.2 <span class=\"nowrap\">micromol/L]</span> or greater increase in serum creatinine or a 1 <span class=\"nowrap\">mg/dL</span> [88.4 <span class=\"nowrap\">micromol/L]</span> or greater increase if the baseline creatinine was &gt;2 <span class=\"nowrap\">mg/dL</span> [177 <span class=\"nowrap\">micromol/L])</span> [<a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/19\" class=\"abstract_t\">19</a>]. Patients who did and did not develop AKI received similar total mannitol doses (7.9&plusmn;9.3 versus 10.2&plusmn;10.7 <span class=\"nowrap\">g/kg)</span> as well as maximum single mannitol doses (3.4&plusmn;1.9 versus 3.1&plusmn;2 <span class=\"nowrap\">g/kg)</span>. Similarly, there were no differences in the peak osmolality or the osmotic gap before the onset of renal insufficiency. The presence of heart failure and a high APACHE II score were the only factors independently associated with a higher likelihood of mannitol-induced AKI. Renal function spontaneously returned to baseline in all patients. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A larger retrospective study of 432 mannitol-treated patients who were critically ill following a stroke found that the incidence of AKI (defined as a 0.3 <span class=\"nowrap\">mg/dL</span> [26.5 <span class=\"nowrap\">micromol/L]</span> or 50 percent increase in serum creatinine) was only 6.5 percent (with none requiring renal replacement therapy) [<a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/20\" class=\"abstract_t\">20</a>]. Diabetes, lower baseline estimated glomerular filtration rate, higher initial National Institutes of Health Stroke Scale (NIHSS) score, and concurrent use of diuretics increased the risk of mannitol-related AKI. Risk of AKI was greater among those treated with higher <a href=\"topic.htm?path=mannitol-drug-information\" class=\"drug drug_general\">mannitol</a> doses, but this was not statistically significant. The lower incidence of AKI in this study compared with the study mentioned previously may be due to the lower cumulative doses of mannitol that were used or to the fact that none had traumatic brain injury.</p><p/><p>Although tubular vacuolization also may contribute, renal vasoconstriction appears to be of primary importance in this setting, an effect which may be potentiated by the concomitant administration of <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a> [<a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/15\" class=\"abstract_t\">15</a>]. Coadministration of <a href=\"topic.htm?path=furosemide-drug-information\" class=\"drug drug_general\">furosemide</a> may also increase the risk of kidney injury [<a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/18\" class=\"abstract_t\">18</a>].</p><p>AKI can be minimized by keeping the <a href=\"topic.htm?path=mannitol-drug-information\" class=\"drug drug_general\">mannitol</a> dose below 0.25 <span class=\"nowrap\">g/kg</span> every four hours (1.5 <span class=\"nowrap\">g/kg</span> daily) [<a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/3\" class=\"abstract_t\">3</a>]. Patients who develop renal failure appear to recover renal function rapidly if treated with hemodialysis to remove the excess mannitol [<a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/14\" class=\"abstract_t\">14</a>].</p><p class=\"headingAnchor\" id=\"H2252878\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=mannitol-drug-information\" class=\"drug drug_general\">Mannitol</a> acts as an osmotic diuretic, resulting in fluid losses that can lead to both volume depletion and hypernatremia. (See <a href=\"#H3\" class=\"local\">'Volume depletion and hypernatremia'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Retention of <a href=\"topic.htm?path=mannitol-drug-information\" class=\"drug drug_general\">mannitol</a> due to underlying kidney failure or mannitol-induced acute kidney injury (AKI) results in hyperosmolality and osmotic movement of water and potassium out of the cells, which can cause volume expansion, hyponatremia and metabolic acidosis (by dilution), and hyperkalemia. (See <a href=\"#H4\" class=\"local\">'Volume expansion, hyponatremia, hyperkalemia, hypokalemia, and metabolic acidosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The concentration of <a href=\"topic.htm?path=mannitol-drug-information\" class=\"drug drug_general\">mannitol</a> in the plasma can be estimated from the plasma osmolal gap, the difference between the measured plasma osmolality (which includes the contribution of mannitol) and the calculated plasma osmolality (which does not). (See <a href=\"#H5\" class=\"local\">'Plasma osmolal gap'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The plasma osmolal gap should not be allowed to exceed 55 <span class=\"nowrap\">mosmol/kg</span> and the <a href=\"topic.htm?path=mannitol-drug-information\" class=\"drug drug_general\">mannitol</a> dose should not exceed 250 <span class=\"nowrap\">mg/kg</span> every 4 hours when mannitol is used in the treatment of cerebral edema or glaucoma; higher doses can cause reversible acute renal failure. Patients who develop renal failure appear to recover renal function rapidly if treated with hemodialysis to remove the excess mannitol. (See <a href=\"#H6\" class=\"local\">'Acute kidney injury'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/1\" class=\"nounderline abstract_t\">GIPSTEIN RM, BOYLE JD. HYPERNATREMIA COMPLICATING PROLONGED MANNITOL DIURESIS. N Engl J Med 1965; 272:1116.</a></li><li><a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/2\" class=\"nounderline abstract_t\">Aviram A, Pfau A, Czaczkes JW, Ullmann TD. Hyperosmolality with hyponatremia, caused by inappropriate administration of mannitol. Am J Med 1967; 42:648.</a></li><li><a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/3\" class=\"nounderline abstract_t\">Dorman HR, Sondheimer JH, Cadnapaphornchai P. Mannitol-induced acute renal failure. Medicine (Baltimore) 1990; 69:153.</a></li><li><a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/4\" class=\"nounderline abstract_t\">Oster JR, Singer I. Hyponatremia, hyposmolality, and hypotonicity: tables and fables. Arch Intern Med 1999; 159:333.</a></li><li><a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/5\" class=\"nounderline abstract_t\">Manninen PH, Lam AM, Gelb AW, Brown SC. The effect of high-dose mannitol on serum and urine electrolytes and osmolality in neurosurgical patients. Can J Anaesth 1987; 34:442.</a></li><li><a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/6\" class=\"nounderline abstract_t\">Fanous AA, Tick RC, Gu EY, Fenstermaker RA. Life-Threatening Mannitol-Induced Hyperkalemia in Neurosurgical Patients. World Neurosurg 2016; 91:672.e5.</a></li><li><a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/7\" class=\"nounderline abstract_t\">Conte G, Dal Canton A, Imperatore P, et al. Acute increase in plasma osmolality as a cause of hyperkalemia in patients with renal failure. Kidney Int 1990; 38:301.</a></li><li><a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/8\" class=\"nounderline abstract_t\">Nicolis GL, Kahn T, Sanchez A, Gabrilove JL. Glucose-induced hyperkalemia in diabetic subjects. Arch Intern Med 1981; 141:49.</a></li><li><a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/9\" class=\"nounderline abstract_t\">Viberti GC. Glucose-induced hyperkalaemia: A hazard for diabetics? Lancet 1978; 1:690.</a></li><li><a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/10\" class=\"nounderline abstract_t\">Seo W, Oh H. Alterations in serum osmolality, sodium, and potassium levels after repeated mannitol administration. J Neurosci Nurs 2010; 42:201.</a></li><li class=\"breakAll\">Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.607.</li><li><a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/12\" class=\"nounderline abstract_t\">DiNubile MJ. Serum osmolality (letter). N Engl J Med 1984; 310:1609.</a></li><li><a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/13\" class=\"nounderline abstract_t\">Garc&iacute;a-Morales EJ, Cariappa R, Parvin CA, et al. Osmole gap in neurologic-neurosurgical intensive care unit: Its normal value, calculation, and relationship with mannitol serum concentrations. Crit Care Med 2004; 32:986.</a></li><li><a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/14\" class=\"nounderline abstract_t\">Gadallah MF, Lynn M, Work J. Case report: mannitol nephrotoxicity syndrome: role of hemodialysis and postulate of mechanisms. Am J Med Sci 1995; 309:219.</a></li><li><a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/15\" class=\"nounderline abstract_t\">Visweswaran P, Massin EK, Dubose TD Jr. Mannitol-induced acute renal failure. J Am Soc Nephrol 1997; 8:1028.</a></li><li><a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/16\" class=\"nounderline abstract_t\">P&eacute;rez-P&eacute;rez AJ, Pazos B, Sobrado J, et al. Acute renal failure following massive mannitol infusion. Am J Nephrol 2002; 22:573.</a></li><li><a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/17\" class=\"nounderline abstract_t\">Better OS, Rubinstein I, Winaver JM, Knochel JP. Mannitol therapy revisited (1940-1997). Kidney Int 1997; 52:886.</a></li><li><a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/18\" class=\"nounderline abstract_t\">Dickenmann M, Oettl T, Mihatsch MJ. Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis 2008; 51:491.</a></li><li><a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/19\" class=\"nounderline abstract_t\">Gondim Fde A, Aiyagari V, Shackleford A, Diringer MN. Osmolality not predictive of mannitol-induced acute renal insufficiency. J Neurosurg 2005; 103:444.</a></li><li><a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/20\" class=\"nounderline abstract_t\">Lin SY, Tang SC, Tsai LK, et al. Incidence and Risk Factors for Acute Kidney Injury Following Mannitol Infusion in Patients With Acute Stroke: A Retrospective Cohort Study. Medicine (Baltimore) 2015; 94:e2032.</a></li><li><a href=\"https://www.uptodate.com/contents/complications-of-mannitol-therapy/abstract/21\" class=\"nounderline abstract_t\">Kim MY, Park JH, Kang NR, et al. Increased risk of acute kidney injury associated with higher infusion rate of mannitol in patients with intracranial hemorrhage. J Neurosurg 2014; 120:1340.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2333 Version 11.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H2252878\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">COMPLICATIONS</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Volume depletion and hypernatremia</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Volume expansion, hyponatremia, hyperkalemia, hypokalemia, and metabolic acidosis</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Plasma osmolal gap</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Acute kidney injury</a></li></ul></li><li><a href=\"#H2252878\" id=\"outline-link-H2252878\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=angle-closure-glaucoma\" class=\"medical medical_review\">Angle-closure glaucoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diabetic-ketoacidosis-and-hyperosmolar-hyperglycemic-state-in-adults-clinical-features-evaluation-and-diagnosis\" class=\"medical medical_review\">Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Clinical features, evaluation, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-and-management-of-elevated-intracranial-pressure-in-adults\" class=\"medical medical_review\">Evaluation and management of elevated intracranial pressure in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hyponatremia-following-transurethral-resection-or-hysteroscopy\" class=\"medical medical_review\">Hyponatremia following transurethral resection or hysteroscopy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=serum-osmolal-gap\" class=\"medical medical_review\">Serum osmolal gap</a></li></ul></div></div>","javascript":null}